New data has been released on the use of CAR-T therapy in autoimmune disease, indicating both promise and challenges. Several pharmaceutical companies, including Kyverna, UCB, and Gilead, are making significant investments in treatments for autoimmune diseases, including cell therapies and bispecifics. The development of these treatments is ongoing, with some companies following approaches similar to those used in oncology, while others are exploring new methods, such as "in vivo" cell therapy.